Publications by authors named "Peter Cheverton"

Claim this Profile
D
Development and validation of a predictive model to guide the use of plerixafor in pediatric population.
Bernard Sebastien, Peter Cheverton, Catherine Magnin, Jihane Aouni, Remi Castan

Bone Marrow Transplant· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.
Leslie A Andritsos, John C Byrd, Peter Cheverton, Jingyang Wu, Mariela Sivina

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
John Kuruvilla, Cheng-Hwai Tzeng, Seok-Goo Cho, Seok Jin Kim, Jih-Luh Tang, Peter Cheverton

Bone Marrow Transplant· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Ivana N Micallef, Patrick J Stiff, Auayporn P Nademanee, Richard T Maziarz, Mitchell E Horwitz, Peter D Cheverton

Biol Blood Marrow Transplant· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Kevin B Kim, Jeffrey A Sosman, John P Fruehauf, Gerald P Linette, Svetomir N Markovic, Peter Cheverton

J Clin Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Moritz N Wente, Jörg Kleeff, Markus W Büchler, Jantien Wanders, Peter Cheverton

Invest New Drugs· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Otto Soepenberg, Maja J A de Jonge, Alex Sparreboom, Peter de Bruin, Ferry A L M Eskens, Peter Cheverton

Clin Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis